Description:
This invention reports pharmacoperones for their novel use of therapeutics in the treatment of nephrogenic diabetes insipidus (NDI). Pharmacoperones are small molecules that enter the cell and serve as a scaffolding to allow mutated proteins to route correctly. In NDI, there is a mutation in the V2 receptor protein. Here, the inventor has reported over 140 pharmacoperones to the V2 receptor; therefore, the pharmacoperones may act as drugs specifically against the known pathology of NDI.
Reference Number: D-1209
Market Applications:
Features, Benefits & Advantages:
- Non-antagonist pharmacoperones for nephrogenic diabetes insipidus treatment
Intellectual Property:
A Provisional Application was filed in October of 2015 and converted to a PCT application in October of 2016.
Development Stage:
This technology is still being tested; however, the compounds have been identified and experimentally confirmed. Animal, pre-clinical, and clinical studies are in the near future.
Researchers:
Michael Conn, Ph.D., Sr. Vice President for Research, Associate Provost and Professor of Internal Medicine and Cell Biology, Texas Tech University Health Sciences Center, Lubbock, Texas.
Keywords: pharmacoperone, nephrogenic diabetes insipidus, mutant, V2 receptor